CCTR yields 200000000.00% · ABBV yields 3.06%● Live data
📍 CCTR pulled ahead of the other in Year 1
Combined, CCTR + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CCTR + ABBV for your $10,000?
China Crescent Enterprises, Inc., through its subsidiaries, provides information technology products and services, and systems integration services in the People's Republic of China. It offers consulting, development, implementation, and maintenance services for technology systems, which include software and hardware peripherals for computing, communication, and data exchanges related to general business application, as well as specialty fields of medical, security, military, and homeland defense applications. The company also involves in the prototype development of security systems and original equipment manufacturer sourcing for the production of hardware. In addition, it engages in the resale of IT products, including notebook and desktop computers, printers, servers, network equipment, as well as operating systems, database, middleware, and application software. Further, the company manufactures wireless communication terminals, including GSM, GSM/GPRS modules, GPS modules, GPS trackers, and personal navigation devices. It has a strategic partnership with Gaozhi Science and Technology Development, LTD. to develop and distribute high technology products and services. The company was formerly known as NewMarket China, Inc. and changed its name to China Crescent Enterprises, Inc. in June 2008. China Crescent Enterprises, Inc. is headquartered in Dallas, Texas. China Crescent Enterprises, Inc. is a subsidiary of NewMarket Technology, Inc.
Full CCTR Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.